Monday, Dec 18, 1995
South San Francisco, Calif. -- December 18, 1995 --Genentech, Inc. (NYSE:GNE) today announced that the European Patent Office has rejected an appeal by Boehringer Mannheim, Cell Tech Limited, and the Wellcome Foundation, and has upheld the granting of Genentech's patent relating to tissue plasminogen activator (t-PA) in Europe.
The patent claims cover the preparation of a tissue plasminogen activator protein by expression in a recombinant host organism and includes recombinant human t-PA, alleles and derivatives by way of deletion, substitution, insertion, addition, or replacement of its amino acids.
"We are gratified that the European Patent Office sustained the granting of our patent with broad claims. We believe that this will enhance Genentech's and our licensee's position in the area of thrombolytic therapy," said Stephen Raines, Genentech's vice president of Intellectual Property.
Boehringer Ingelheim GmbH is the exclusive licensee of Genentech's t-PA in Europe.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures, and markets human pharmaceuticals for significant unmet medical needs. The Company has headquarters in South San Francisco and is traded on the New York and Pacific stock exchanges under the symbol GNE.
# # #